NSAID use and the risk of colorectal adenomas and colorectal cancer in the PLCO Cancer Screening Trial
Despite their promise, there are many unanswered questions about the use of NSAIDs in this regard, and they have not yet been adopted for widespread chemoprophylaxis. There are knowledge gaps regarding the magnitude of association for NSAIDs with colorectal adenoma and colorectal cancer, and their role in colorectal tumorigenesis (i.e. the initiation vs. progression of colorectal tumors) remains unclear. Additionally, because the significant adverse effects of these drugs preclude indiscriminate use, there is a need to clearly delineate the appropriate patient sub-groups that will be most likely to benefit from chemoprophylaxis.
Using data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we propose to prospectively evaluate the association between the use of NSAIDs and the risk of colorectal adenoma, adenoma recurrence, and colorectal cancer. Furthermore, we will evaluate this association within sub-groups of the study population, including age, sex and colorectal cancer family history, to identify the optimal patient characteristics for chemoprophylaxis with NSAIDs.
-Investigate the association between the self-reported use of NSAIDs and the risk of incident adenoma, recurrent adenoma and colorectal cancer in the PLCO cohort, overall and by tumor location
-Estimate the association between the use of NSAIDs and the risk of colorectal cancer in specific sub-populations, by stratifying on factors such as age, sex and family history of colorectal cancer
Wen-Yi Huang, Ph.D., M.S.P.H., NCI
Sonja I. Berndt, Pharm.D., Ph.D., NCI
Kenechukwu Chudy-Onwugaje, M.B.B.S, M.P.H, University of Maryland School of Medicine
Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial.
Chudy-Onwugaje K, Huang WY, Su LJ, Purdue MP, Johnson CC, Wang L, Katki HA, Barry KH, Berndt SI
Cancer. 2021 May 11 PUBMED